G

ood morning, everyone. Damian Garde here, in for Ed Silverman once more, and with another round of headlines to get your day started.

UK regulators say Bristol-Myers Squibb’s blockbuster cancer drug Opdivo is too expensive for patients with head and neck cancer, PharmaTimes tells us. According to the National Institute for Health and Care Excellence, the nation’s drug pricing watchdog, Opdivo’s cost, about £5,700 (or $7,000) a month, doesn’t justify its effect on quality of life. NICE made a similar ruling on Opdivo’s use in lung cancer last year.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy